시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 비교리스트
세계의 인간 면역 결핍 바이러스 치료제 시장 보고서(2025년)
Human Immunodeficiency Virus Therapeutics Global Market Report 2025
상품코드 : 1751018
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,160,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 8,904,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 11,649,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

인간 면역 결핍 바이러스 치료제 시장 규모는 향후 수년간 강력한 성장이 예상될 예정입니다. 무방비한 성행위의 급증, 정부 주도의 프로그램의 확대 등에 기인한다고 생각됩니다. 예측 기간에 있어서의 주요한 동향으로서는 기술의 진보, AI를 활용한 의약품 개발, 장시간 작용형 주사 치료의 출현, 원격 의료의 통합, CRISPR을 활용한 유전자 치료의 탐구 등을 들 수 있습니다.

무방비 성행위 발생률의 상승은 인간 면역결핍 바이러스(HIV) 치료제 시장의 성장을 가속하는 주요인입니다. 피임 기구 없이 하는 성관계로 정의되는 무방비 성관계는 HIV를 포함한 성병(STI) 위험을 현저히 높입니다. 이러한 추세는 피임 방법에 대한 접근성이 제한적이고 특히 청소년과 청소년 사이에서 포괄적인 성교육이 이루어지지 않아 더욱 악화되고 있습니다. HIV 치료제는 바이러스 부하를 억제하여 전염을 예방하고 환자 결과를 개선하는 데 중요한 역할을 합니다. 미국 질병통제예방센터(CDC)의 2024년 11월 보고서에 따르면 2023년에 조사된 미국 고등학생의 32%가 성관계를 가졌다고 답했으며, 48%는 최근 만남에서 콘돔을 사용하지 않았다고 답했습니다.

HIV 치료제 시장의 주요 기업은 효능을 향상시키고 약물 내성을 최소화하고 환자의 어드레싱을 촉진하기 위해 병용 요법 전략을 진행하고 있습니다. 병용 요법은 HIV 치료를 위해 두 가지 이상의 약물을 동시에 사용하는 것을 포함하며, 바이러스 조절 개선, 알약 부담 감소, 저항성 발생 위험 감소 등 여러 가지 이점을 제공합니다. 2022년 12월, 미국에 본사를 둔 바이오 제약 회사인 길리어드 사이언스는 새로운 지속형 캡시드 억제제인 산렌카(레나카파비르)에 대한 FDA 승인을 받았습니다.다른 항레트로바이러스약과의 병용으로 승인된 산렌카는 다제 내성 HIV-1의 성인을 대상으로 하고 있습니다. 이 약물은 동급 최초의 HIV 치료제로, 2년에 한 번 복용하는 요법을 제공하여 편의성과 순응도를 크게 향상시킵니다. 이번 승인은 강력하고 지속적인 바이러스학적 억제를 나타낸 CAPELLA 시험에 의해 뒷받침되었습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

SHW
영문 목차

영문목차

Human immunodeficiency virus (HIV) therapeutics refer to treatments and medications aimed at managing and suppressing HIV infection, primarily through antiretroviral therapy (ART). These therapies work to lower the viral load, prevent the progression to AIDS, and enhance the quality of life for people living with HIV.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary drug types in HIV therapeutics include branded and generic drugs. Branded drugs are patented treatments developed and marketed under specific trade names after extensive research and clinical evaluation to ensure efficacy and safety. The major drug classes encompass nucleoside-analog reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), entry and fusion inhibitors, protease inhibitors (PIs), integrase inhibitors, and coreceptor antagonists. These medications are distributed via hospital pharmacies, online platforms, and retail pharmacies and are utilized by end users such as hospitals, clinics, and specialty treatment centers.

The human immunodeficiency virus therapeutics market research report is one of a series of new reports from The Business Research Company that provides human immunodeficiency virus therapeutics market statistics, including the human immunodeficiency virus therapeutics industry global market size, regional shares, competitors with the human immunodeficiency virus therapeutics market share, detailed human immunodeficiency virus therapeutics market segments, market trends, and opportunities, and any further data you may need to thrive in the human immunodeficiency virus therapeutics industry. This human immunodeficiency virus therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The human immunodeficiency virus therapeutics market size has grown strongly in recent years. It will grow from$14.11 billion in 2024 to $14.94 billion in 2025 at a compound annual growth rate (CAGR) of 5.8%. The growth during the historic period can be attributed to the increasing prevalence of HIV, expansion of awareness initiatives, a rise in diagnostic testing, greater penetration of generic drugs, and the development of healthcare infrastructure.

The human immunodeficiency virus therapeutics market size is expected to see strong growth in the next few years. It will grow to$18.57 billion in 2029 at a compound annual growth rate (CAGR) of 5.6%. The growth during the forecast period can be attributed to an increasing HIV patient population, a rise in HIV screening efforts, growth in voluntary testing rates, a surge in unprotected sexual practices, and the expansion of government-led programs. Major trends in the forecast period include advancements in technology, AI-driven drug development, the emergence of long-acting injectable treatments, the integration of telemedicine, and the exploration of CRISPR-based gene therapies.

The rising incidence of unprotected sexual activity is a key factor propelling the growth of the human immunodeficiency virus (HIV) therapeutics market. Unprotected sex-defined as sexual activity without the use of barrier protection-significantly elevates the risk of sexually transmitted infections (STIs), including HIV. This trend is exacerbated by limited access to contraceptive methods and the absence of comprehensive sex education, particularly among adolescents and young adults. HIV therapeutics play a critical role in suppressing viral load, thereby preventing transmission and improving patient outcomes. For example, according to a November 2024 report from the Centers for Disease Control and Prevention (CDC), 32% of U.S. high school students surveyed in 2023 reported having had sexual intercourse, and 48% did not use a condom during their most recent encounter. These statistics highlight the urgent need for effective HIV interventions and support the growing demand for antiretroviral therapies.

Leading companies in the HIV therapeutics market are advancing combination therapy strategies to improve efficacy, minimize drug resistance, and promote patient adherence. Combination therapy involves using two or more drugs simultaneously to treat HIV, offering several benefits such as improved virologic control, reduced pill burden, and lower risk of resistance development. In December 2022, Gilead Sciences Inc., a U.S.-based biopharmaceutical firm, received FDA approval for Sunlenca (lenacapavir), a novel long-acting capsid inhibitor. Approved for use in combination with other antiretroviral agents, Sunlenca is intended for adults with multidrug-resistant HIV-1. It is the first HIV medication in its class and offers a biannual dosing regimen, which significantly enhances convenience and adherence. The approval was supported by the CAPELLA trial, which demonstrated strong and sustained virologic suppression. Innovations such as Sunlenca are reshaping the treatment landscape, especially for patients with complex therapeutic histories.

In May 2022, F. Hoffmann-La Roche Ltd., a Switzerland-based healthcare and diagnostics leader, entered into a partnership with The Global Fund to strengthen HIV and tuberculosis diagnostics in low- and middle-income countries (LMICs). The initiative aims to scale up access to diagnostic tools, overcome infrastructure barriers, and promote sustainable healthcare waste management practices. The Global Fund, also based in Switzerland, is a global financing mechanism dedicated to supporting healthcare systems in the fight against HIV/AIDS, tuberculosis, and malaria. This collaboration reflects a broader industry trend of public-private partnerships targeting improved disease detection, early treatment, and pandemic preparedness in underserved regions.

Major players in the human immunodeficiency virus therapeutics market are Pfizer Inc., Johnson & Johnson, F Hoffmann La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Sanofi SA, Bristol Myers Squibb Company (BMS), Novartis International AG, GlaxoSmithKline plc (GSK), Gilead Sciences Inc., Moderna Inc., BioNTech SE, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Aurobindo Pharma Limited, Cipla Limited, Hetero Labs Limited, Gilead Sciences Inc. / Kite Pharma Inc. (for CAR T HIV cure research), Vir Biotechnology Inc., Theratechnologies Inc., and CytoDyn Inc.

North America was the largest region in the human immunodeficiency virus therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in human immunodeficiency virus therapeutics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the human immunodeficiency virus therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The human immunodeficiency virus therapeutics market consists of revenues earned by entities by providing services such as telehealth and remote patient monitoring, patient support and case management services, clinical trials and research services, and HIV testing and diagnosis services. The market value includes the value of related goods sold by the service provider or included within the service offering. The human immunodeficiency virus therapeutics market also includes sales of antiretroviral drugs (ARVs), pre-exposure prophylaxis (PrEP), post-exposure prophylaxis (PEP), and immune system boosters. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Human Immunodeficiency Virus Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on human immunodeficiency virus therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for human immunodeficiency virus therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The human immunodeficiency virus therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Human Immunodeficiency Virus Therapeutics Market Characteristics

3. Human Immunodeficiency Virus Therapeutics Market Trends And Strategies

4. Human Immunodeficiency Virus Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Human Immunodeficiency Virus Therapeutics Growth Analysis And Strategic Analysis Framework

6. Human Immunodeficiency Virus Therapeutics Market Segmentation

7. Human Immunodeficiency Virus Therapeutics Market Regional And Country Analysis

8. Asia-Pacific Human Immunodeficiency Virus Therapeutics Market

9. China Human Immunodeficiency Virus Therapeutics Market

10. India Human Immunodeficiency Virus Therapeutics Market

11. Japan Human Immunodeficiency Virus Therapeutics Market

12. Australia Human Immunodeficiency Virus Therapeutics Market

13. Indonesia Human Immunodeficiency Virus Therapeutics Market

14. South Korea Human Immunodeficiency Virus Therapeutics Market

15. Western Europe Human Immunodeficiency Virus Therapeutics Market

16. UK Human Immunodeficiency Virus Therapeutics Market

17. Germany Human Immunodeficiency Virus Therapeutics Market

18. France Human Immunodeficiency Virus Therapeutics Market

19. Italy Human Immunodeficiency Virus Therapeutics Market

20. Spain Human Immunodeficiency Virus Therapeutics Market

21. Eastern Europe Human Immunodeficiency Virus Therapeutics Market

22. Russia Human Immunodeficiency Virus Therapeutics Market

23. North America Human Immunodeficiency Virus Therapeutics Market

24. USA Human Immunodeficiency Virus Therapeutics Market

25. Canada Human Immunodeficiency Virus Therapeutics Market

26. South America Human Immunodeficiency Virus Therapeutics Market

27. Brazil Human Immunodeficiency Virus Therapeutics Market

28. Middle East Human Immunodeficiency Virus Therapeutics Market

29. Africa Human Immunodeficiency Virus Therapeutics Market

30. Human Immunodeficiency Virus Therapeutics Market Competitive Landscape And Company Profiles

31. Human Immunodeficiency Virus Therapeutics Market Other Major And Innovative Companies

32. Global Human Immunodeficiency Virus Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Human Immunodeficiency Virus Therapeutics Market

34. Recent Developments In The Human Immunodeficiency Virus Therapeutics Market

35. Human Immunodeficiency Virus Therapeutics Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기